Drug intelligence / Profile preview

ProphaLytic-Vc

Development stage: Preclinical
Lead developer: PhagePro
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

ProphaLytic-Vc (PVC) is an oral, solid-dose bacteriophage therapy being developed by PhagePro for the prevention of cholera. It consists of a cocktail of three lytic bacteriophages specifically designed to target and kill *Vibrio cholerae*, the causative agent of cholera, without disrupting the host's gastrointestinal microbiome. Intended for prophylactic use in high-risk communities, PVC aims to provide immediate protection and prevent the spread of the disease, particularly in the two-week window before cholera vaccines become effective. The formulation is designed to be stable in hot and humid conditions without refrigeration, making it suitable for resource-limited settings in Asia and Africa.

Beyond the preview

Go deeper on ProphaLytic-Vc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProphaLytic-Vc.

Explore the full profile